Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Clin Oncol. 2009 Nov;6(11):670-4. doi: 10.1038/nrclinonc.2009.148.

Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine.

Author information

  • 1UO Oncologia Medica 2 Universitaria, Ospedale Santa Chiara, Pisa, Italy. gl.masi@tin.it

Abstract

BACKGROUND:

A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver. She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective.

INVESTIGATIONS:

Physical examination, laboratory test, chromogranin A test, CT scan, (111)In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scan, (18)F-FDG-PET scan, fine-needle and tissue core liver biopsies.

DIAGNOSIS:

Pulmonary spindle-cell carcinoid tumor with metastases to mediastinal lymph nodes and liver.

MANAGEMENT:

Systemic treatment with oral capecitabine (1,500 mg/m(2) daily from day 1 to day 21) and intravenous liposomal doxorubicin (10 mg/m(2) on days 1, 8 and 15), both repeated every 4 weeks, administered concomitantly with long-acting octreotide 30 mg every 3 weeks. The patient achieved a significant and long-lasting response with the combination of capecitabine and liposomal doxorubicin. She reported no severe adverse effects.

PMID:
19861994
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk